Gland Pharma Ltd (GLAND) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003443,
    "name": "Gland Pharma",
    "stock_name": "Gland Pharma",
    "full_name": "Gland Pharma Ltd",
    "name_url": "stocks-analysis/gland-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,891.00",
    "chg": -6.4,
    "chgp": "-0.34%",
    "dir": -1,
    "prev_price": "1,897.40",
    "mcapval": "31,600.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543245,
    "symbol": "GLAND",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE068V01023",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "3.87 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/gland-pharma-1003443-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Gland Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-gland-pharma-technically-bullish-or-bearish-3740791",
        "imagepath": "",
        "date": "2025-12-02 09:37:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Technical Trend</strong></p>\n<p>As of 1 December 2025, Gland Pharma’s technical trend has transitioned from mildly bearish to a sideways pattern. This shift indicates a pause in the previous downward momentum, suggesting that the stock may be consolidating rather than continuing a clear decline or rally. Sideways trends often reflect market indecision, where neither buyers nor sellers dominate, and can precede either a reversal or continuation of the prior trend.</p>\n<p>Such a neutral stance is important for investors to recognise, as it implies that the stock is currently in a phase of equilibrium, awaiting fresh catalysts or market developments to determine its next directional move.</p>\n<p><strong>Key Technical Indicators: Mixed Signals</strong></p>\n<p>Examining the de..."
      },
      {
        "title": "Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-amid-market-underperformance-3740397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GlandPharma_technicaldot_3740397.png",
        "date": "2025-12-02 08:12:06",
        "description": "Gland Pharma’s recent trading activity reflects a nuanced shift in technical momentum, with key indicators signalling a transition from a mildly bearish stance to a more sideways trend. This development comes amid a backdrop of mixed signals from moving averages, MACD, RSI, and other technical tools, offering investors a complex picture of the stock’s near-term trajectory."
      },
      {
        "title": "Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-amid-mixed-market-signals-3737545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GlandPharma_technicaldot_3737545.png",
        "date": "2025-12-01 08:04:50",
        "description": "Gland Pharma’s recent technical indicators reveal a nuanced shift in price momentum, reflecting a transition from a sideways trend to a mildly bearish stance. While some metrics suggest caution, others indicate pockets of resilience, underscoring the complexity of the stock’s current market behaviour within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-amid-mixed-market-signals-3734741",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlandPharma_technicaldot_3734741.png",
        "date": "2025-11-28 08:07:49",
        "description": "Gland Pharma’s stock has experienced a notable shift in price momentum, reflecting a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a more sideways movement. This development comes amid a backdrop of mixed signals from key technical tools such as MACD, RSI, Bollinger Bands, and moving averages, underscoring a period of consolidation for the pharmaceutical company’s shares."
      },
      {
        "title": "Gland Pharma Shows Mixed Technical Signals Amid Mildly Bullish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-to-mildly-bullish-amid-mixed-indicator-signals-3732596",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlandPharma_technicaldot_3732596.png",
        "date": "2025-11-27 08:08:39",
        "description": "Gland Pharma’s recent price action reflects a nuanced shift in momentum, with technical indicators presenting a blend of mildly bullish and bearish signals. The stock’s movement from a sideways trend to a mildly bullish stance invites closer examination of key metrics such as MACD, RSI, moving averages, and volume-based indicators to understand the evolving market sentiment."
      },
      {
        "title": "Gland Pharma’s Market Assessment Reflects Mixed Signals Amidst Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gland-pharma-upgraded-to-hold-by-marketsmojo-amid-mixed-financial-and-technical-signals-3727925",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlandPharma_mojoScore_3727925.png",
        "date": "2025-11-25 08:59:45",
        "description": "Gland Pharma’s recent market evaluation reveals a nuanced picture shaped by a combination of technical indicators, valuation metrics, financial trends, and quality parameters. Despite a largely flat financial performance in the latest quarter, shifts in market assessment highlight the complexities investors face when analysing this pharmaceutical and biotechnology company."
      },
      {
        "title": "Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-amid-mixed-market-signals-3727683",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlandPharma_technicaldot_3727683.png",
        "date": "2025-11-25 08:14:29",
        "description": "Gland Pharma’s stock price momentum has entered a phase of sideways movement following a period of mild bullishness, reflecting a complex interplay of technical indicators that suggest a nuanced market assessment for the pharmaceutical company."
      },
      {
        "title": "How has been the historical performance of Gland Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-gland-pharma-3726434",
        "imagepath": "",
        "date": "2025-11-24 23:26:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Gland Pharma’s net sales have shown a robust upward trend over the six-year period, rising from ₹2,633 crore in March 2020 to ₹5,616 crore in March 2025. This near doubling of sales reflects the company’s expanding market presence and product portfolio. However, the growth was not strictly linear; for instance, sales dipped slightly from ₹5,664 crore in March 2024 to ₹5,616 crore in March 2025, indicating some recent market pressures or operational challenges.</p>\n<p>Operating profit margins, excluding other income, have contracted from a high of 37.6% in March 2021 to 22.6% in March 2025. This decline suggests rising costs or pricing pressures impacting core profitability. Despite this, the company maintained a healthy gross profit margin abo..."
      },
      {
        "title": "Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gland-pharma-technical-momentum-shifts-amid-mixed-market-signals-3719760",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlandPharma_technicaldot_3719760.png",
        "date": "2025-11-21 08:09:11",
        "description": "Gland Pharma’s stock price has exhibited a nuanced shift in momentum, reflecting a complex interplay of technical indicators across weekly, monthly, and daily timeframes. While some metrics suggest emerging bullish tendencies, others continue to signal caution, underscoring the importance of a measured approach to the pharmaceutical company’s market movements."
      }
    ],
    "total": 303,
    "sid": "1003443",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/gland-pharma-1003443"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "01-Feb-2026",
      "details": "Schedule of Investors Meet",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "29-Jan-2026",
      "details": "Copy of News Paper Publication on Q3FY26 Financial Results",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "29-Jan-2026",
      "details": "Retirement of Mr. Satnam Singh Loomba as Chief Operating Officer of the Company from the close of business hours of March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gland Pharma Ltd has declared <strong>1800%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Gland Pharma technically bullish or bearish?

2025-12-02 09:37:10

Overview of Current Technical Trend As of 1 December 2025, Gland Pharma’s technical trend has transitioned from mildly bearish to a sideways pattern. This shift indicates a pause in the previous downward momentum, suggesting that the stock may be consolidating rather than continuing a clear decline or rally. Sideways trends often reflect market indecision, where neither buyers nor sellers dominate, and can precede either a reversal or continuation of the prior trend. Such a neutral stance is important for investors to recognise, as it implies that the stock is currently in a phase of equilibrium, awaiting fresh catalysts or market developments to determine its next directional move. Key Technical Indicators: Mixed Signals Examining the de...

Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:12:06

Gland Pharma’s recent trading activity reflects a nuanced shift in technical momentum, with key indicators signalling a transition from a mildly bearish stance to a more sideways trend. This development comes amid a backdrop of mixed signals from moving averages, MACD, RSI, and other technical tools, offering investors a complex picture of the stock’s near-term trajectory.

Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-01 08:04:50

Gland Pharma’s recent technical indicators reveal a nuanced shift in price momentum, reflecting a transition from a sideways trend to a mildly bearish stance. While some metrics suggest caution, others indicate pockets of resilience, underscoring the complexity of the stock’s current market behaviour within the Pharmaceuticals & Biotechnology sector.

Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-11-28 08:07:49

Gland Pharma’s stock has experienced a notable shift in price momentum, reflecting a complex interplay of technical indicators that suggest a transition from a mildly bullish trend to a more sideways movement. This development comes amid a backdrop of mixed signals from key technical tools such as MACD, RSI, Bollinger Bands, and moving averages, underscoring a period of consolidation for the pharmaceutical company’s shares.

Gland Pharma Shows Mixed Technical Signals Amid Mildly Bullish Momentum

2025-11-27 08:08:39

Gland Pharma’s recent price action reflects a nuanced shift in momentum, with technical indicators presenting a blend of mildly bullish and bearish signals. The stock’s movement from a sideways trend to a mildly bullish stance invites closer examination of key metrics such as MACD, RSI, moving averages, and volume-based indicators to understand the evolving market sentiment.

Gland Pharma’s Market Assessment Reflects Mixed Signals Amidst Flat Financials

2025-11-25 08:59:45

Gland Pharma’s recent market evaluation reveals a nuanced picture shaped by a combination of technical indicators, valuation metrics, financial trends, and quality parameters. Despite a largely flat financial performance in the latest quarter, shifts in market assessment highlight the complexities investors face when analysing this pharmaceutical and biotechnology company.

Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:14:29

Gland Pharma’s stock price momentum has entered a phase of sideways movement following a period of mild bullishness, reflecting a complex interplay of technical indicators that suggest a nuanced market assessment for the pharmaceutical company.

How has been the historical performance of Gland Pharma?

2025-11-24 23:26:56

Revenue and Profitability Trends Gland Pharma’s net sales have shown a robust upward trend over the six-year period, rising from ₹2,633 crore in March 2020 to ₹5,616 crore in March 2025. This near doubling of sales reflects the company’s expanding market presence and product portfolio. However, the growth was not strictly linear; for instance, sales dipped slightly from ₹5,664 crore in March 2024 to ₹5,616 crore in March 2025, indicating some recent market pressures or operational challenges. Operating profit margins, excluding other income, have contracted from a high of 37.6% in March 2021 to 22.6% in March 2025. This decline suggests rising costs or pricing pressures impacting core profitability. Despite this, the company maintained a healthy gross profit margin abo...

Gland Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-11-21 08:09:11

Gland Pharma’s stock price has exhibited a nuanced shift in momentum, reflecting a complex interplay of technical indicators across weekly, monthly, and daily timeframes. While some metrics suggest emerging bullish tendencies, others continue to signal caution, underscoring the importance of a measured approach to the pharmaceutical company’s market movements.

View All News